Olanzapine may help control nausea, vomiting in patients with advanced cancer
(Mayo Clinic) Olanzapine, a generic drug used to treat nervous, emotional and mental conditions, also may help patients with advanced cancer successfully manage nausea and vomiting unrelated to chemotherapy. These are the findings of a study published Thursday, May 7, 2020 in JAMA Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 7, 2020 Category: International Medicine & Public Health Source Type: news
Olanzapine may help control nausea, vomiting in patients with advanced cancer
ROCHESTER, Minn. ? Olanzapine, a generic drug used to treat nervous, emotional and mental conditions, also may help patients with advanced cancer successfully manage nausea and vomiting unrelated to chemotherapy. These are the findings of a study published Thursday, May 7 in JAMA Oncology. Charles Loprinzi, M.D., a Mayo Clinic medical oncologist, played a leadership role [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 6, 2020 Category: Databases & Libraries Source Type: news
How an Antipsychotic Became Widely Used as an Antiemetic How an Antipsychotic Became Widely Used as an Antiemetic
All major guidelines now recommend olanzapine for chemotherapy-induced nausea and vomiting, but the drug has never been formally approved for this use. It was launched as an antipsychotic.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 6, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
' Major Impact': Olanzapine for CINV at 5 mg, Not 10 mg'Major Impact': Olanzapine for CINV at 5 mg, Not 10 mg
The antipsychotic olanzapine is used off label as an antiemetic, but the 10-mg dose causes daytime sedation. Now a phase 3 trial suggests that 5 mg is just as effective.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 2, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Chinese strategy: Dr Reddy's outsources part manufacturing to local parties
The company which won the tender to market Olanzapine drug in China, is expected to launch it beginning next year, the official said. The products are manufactured either in the plant owned by KRRP in China, or partners in China, or in India by Dr. Reddy's, the official further said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 20, 2019 Category: Pharmaceuticals Source Type: news
Olanzapine After Psychotic Depression Remission Cuts Relapses Olanzapine After Psychotic Depression Remission Cuts Relapses
Although patients in remission from psychotic depression can benefit from continuation of an antipsychotic, they may pay for it in weight gain, new research suggests.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 23, 2019 Category: Internal Medicine Tags: Psychiatry News Source Type: news
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Following Pre-NDA Meeting With FDA, Company Plans to Submit New Drug Application for Schizophrenia and Bipolar I Disorder Indications in the Fourth Quarter of 2019
DUBLIN, July 15, 2019 -- (Healthcare Sales & Marketing Network) -- Alkermes plc (Nasdaq:... Biopharmaceuticals, FDA Alkermes, ALKS 3831, olanzapine, samidorphan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 15, 2019 Category: Pharmaceuticals Source Type: news
More Evidence Schizophrenia Combo Therapy Blunts Weight Gain More Evidence Schizophrenia Combo Therapy Blunts Weight Gain
The combination of olanzapine and samidorphan, shown to mitigate the weight gain observed with olanzapine alone in ENLIGHTEN-2, continues to prevent weight gain, new results from an extension study show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
Patient survival after acute voluntary poisoning with a huge dose of oxcarbazepine and olanzapine - Kalogera V, Galopoulos D, Eleftheriotis G, Meimeti E, Malios I, Marathonitis G, Loupa C.
INTRODUCTION: Oxcarbazepine is a carbamazepine pre-drug with less drug interactions. Its adverse effects, including hyponatremia, somnolence and ataxia, are dose dependent. Olanzapine is an atypical antipsychotic drug most commonly used to manage psychoses... (Source: SafetyLit)
Source: SafetyLit - December 8, 2018 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
Novel Schizophrenia Drug Shows'Favorable Weight Profile'Novel Schizophrenia Drug Shows'Favorable Weight Profile '
In topline results from the phase 3 ENLIGHTEN-2 trial, patients with schizophrenia who received olanzapine/samidorphan showed significant less weight gain than those who received olanzapine alone.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news
Novel Antipsychotic Curbed Weight Gain, Drugmaker Says
(MedPage Today) -- Olanzapine/samidorphan showed less weight gain versus olanzapine alone in phase III trial (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 30, 2018 Category: Primary Care Source Type: news
Alkermes shares dip despite 'positive' trial results from schizophrenia drug
Alkermes, one of the state ’s largest drugmakers, announced the results of a late-stage trial of a schizophrenia drug Thursday it calls "positive," but investors appear to have doubts about the drug’s effect on patients’ weight.
Alkermes (Nasdaq: ALKS) has been developing a daily schizophrenia drug, called ALKS 3831, t hat it hopes will compete with Zyprexa, a drug by Eli Lilly (NYSE: LLY), but cause less weight gain in patients.
Results of the Phase 3 clinical trial appeared to show that… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 29, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news
Alkermes schizophrenia treatment meets main goals in late-stage study
Alkermes Plc's treatment for schizophrenia met the main goals in a late-stage study, with patients not gaining as much weight as those treated with commonly used antipsychotic drug olanzapine, the company said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Manitoba paramedics 1st in Canada to offer new medication for meth users
The provincial government will permit paramedics to administer olanzapine to agitated people who have used methamphetamine, Health Minister Cameron Friesen announced on Monday. (Source: CBC | Health)
Source: CBC | Health - November 26, 2018 Category: Consumer Health News Tags: News/Canada/Manitoba Source Type: news
No Gain with Antipsych Meds Switch in Schizophrenia
(MedPage Today) -- Similar rates of remission with continued amisulpride and switch to olanzapine (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 13, 2018 Category: Primary Care Source Type: news
